Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

In an interview with HT Lifestyle, Dr. Rajesh Kumar Reddy Adapala, Department of Uro – oncology & Robotics, Asian Institute ...

It was identified that the patient had a small tonsil tumor that a biopsy revealed to be HPV-positive squamous cell carcinoma. The patient met with the Johns Hopkins Head and Neck Cancer ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 87% of cases. NSCLCs can be broken down into 2 major sub-types: adenocarcinoma (sometimes referred to as ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...